Go Back

Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting

05.09.2023

BOSTON, Mass. and SEATTLE, Wash. – May 9, 2023 – Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data for its oncogenic driver program targeting KRAS G12D, AFNT–212, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, California.

“Our mission is to address the significant unmet needs of patients with hard-to-treat solid tumors by advancing precision immunotherapies that target oncogenic driver mutations,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “We believe gene editing is an important tool in the development of cell therapies as it allows for precise and targeted modifications within cells, aimed to improve safety and activity of these therapies. We look forward to presenting encouraging preclinical data for our gene-edited KRAS G12D-targeting TCR-T cell therapy, AFNT-212, at ASGCT this year.”

Poster presentation details are as follows:

• Abstract: #1691, May 19, 12:00-2:00 pm PT: Novel CRISPR-Associated Gene Editing Systems Enable Efficient and Specific TRAC/TRBC Knockout Triggering Robust Expression and Sensitivity of a T Cell Receptor Specific for Mutant KRAS G12D – Presenting Author: Ankit Gupta, Ph.D., Director of Gene Editing, Affini-T Therapeutics

 

About Affini-T Therapeutics

Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

Contacts:
Media Contact
Danielle Cantey
Evoke Canale
Danielle.Cantey@evokegroup.com
619-826-4657

Investor Contact
Ailsa Dalgliesh, PhD
ailsa@affinittx.com

---

Go Back